Federation Des Caisses Desjardins Du Quebec Nektar Therapeutics Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 30, 2024	SELL	$10.83 - $18.41 $2,869 - $4,878	-265 Closed	0 $0
Q2 2021 Aug 30, 2024	BUY	$16.52 - $20.4 $4,377 - $5,406	265 New	265 $4.55 Million
Q3 2020 Aug 30, 2024	SELL	$16.59 - $24.79 $4,977 - $7,437	-300 Reduced 53.1%	265 $4.4 Million
Q1 2020 Aug 30, 2024	SELL	$14.47 - $27.96 $7,090 - $13,700	-490 Reduced 46.45%	565 $10.1 Million
Q2 2019 Aug 30, 2024	BUY	$31.0 - $36.3 $9,300 - $10,890	300 Added 39.74%	1,055 $37.5 Million
Q1 2019 Aug 30, 2024	BUY	$31.58 - $46.35 $15,474 - $22,711	490 Added 184.91%	755 $25.4 Million
Q4 2018 Aug 30, 2024	BUY	$30.43 - $56.65 $8,063 - $15,012	265 New	265 $8.71 Million
Q3 2018 Aug 30, 2024	BUY	$46.46 - $68.49 $2,230 - $3,287	48 Added 18.11%	313 $19.1 Million
Q2 2018 Aug 30, 2024	SELL	$46.25 - $104.45 $2,312 - $5,222	-50 Reduced 15.87%	265 $12.9 Million
Q1 2018 Aug 30, 2024	BUY	$57.4 - $108.44 $18,081 - $34,158	315 New	315 $33.5 Million

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$17 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$16.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$14 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$10.1 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$9.84 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account